Adverum Biotechnologies I... (ADVM)
2.93
-0.05 (-1.68%)
At close: Apr 17, 2025, 3:59 PM
2.93
0.00%
After-hours: Apr 17, 2025, 04:05 PM EDT
-1.68% (1D)
| Bid | 2.8 |
| Market Cap | 61.21M |
| Revenue (ttm) | -2.6M |
| Net Income (ttm) | -130.93M |
| EPS (ttm) | -6.62 |
| PE Ratio (ttm) | -0.44 |
| Forward PE | -0.71 |
| Analyst | Buy |
| Ask | 3.35 |
| Volume | 285,190 |
| Avg. Volume (20D) | 173,324 |
| Open | 2.94 |
| Previous Close | 2.98 |
| Day's Range | 2.75 - 2.98 |
| 52-Week Range | 2.75 - 11.87 |
| Beta | 1.09 |
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with U...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 155
Stock Exchange NASDAQ
Ticker Symbol ADVM
Website https://www.adverum.com
Analyst Forecast
According to 6 analyst ratings, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 923.89% from the latest price.
Stock ForecastsEarnings Surprise
Adverum Biotechnologies has released their quartely earnings
on Apr 15, 2025:
